BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

OPX Biotechnologies Appoints Daniel W. Muehl as Chief Financial Officer


7/13/2010 9:24:23 AM

BOULDER, CO--(Marketwire - July 13, 2010) -

OPX Biotechnologies Inc. (OPXBIO), a renewable biochemical and biofuel company, today announced that it has strengthened its management team with the appointment of Daniel W. Muehl as chief financial officer.

"Dan brings more than 25 years of executive leadership experience in fast-growing, publicly traded technology companies, during which time he developed expertise in finance and operations management, strategic partnering, fundraising, and mergers and acquisitions," said Charles R. (Chas) Eggert, president and CEO of OPXBIO. "As we work to deliver bio-based products with lower cost and improved sustainability compared to petroleum-based alternatives, Dan's expertise will be essential to the growth and success of the company."

Prior to joining OPXBIO, Dan was vice president of finance at the NASDAQ-listed bio-pharmaceutical company Pharmion Corporation, which was sold in 2008 for $2.5 billion. Prior to Pharmion, Dan served as chief financial officer at biotechnology/bioprocessing company Repligen Corporation from 2006 to 2007 and at medical device manufacturer Physiometrix Inc. from 1998 to 2005. From 1995 to 1998, he served as chief operating officer and chief financial officer of computer graphics design and manufacturing company Number Nine Visual Technology. Dan began his career in public accounting at Ernst & Young and Laventhol & Horwath. He holds a B.S. in accounting from the University of Massachusetts - Amherst and received his CPA certification in 1990.

"OPXBIO has proven its leadership in the bio-based chemical sector with the significant progress it has made in developing its first product, bio-based acrylic," said Dan Muehl, chief financial officer of OPXBIO. "We will be first to market with bio-based acrylic and will follow that with additional products that are also less expensive and more sustainable than their petroleum-based counterparts. I am confident this will grow the company's value substantially over time."

About OPXBIO
OPXBIO is a Colorado-based company using biotechnology to convert renewable raw materials into biochemicals and biofuels. Applying its EDGE™ (Efficiency Directed Genome Engineering) technology, OPXBIO will manufacture bio-based products that are more economical and sustainable than petroleum-based alternatives. OPXBIO has already demonstrated laboratory-scale production of several different biochemicals and biofuels using renewable biomass as well as carbon dioxide and hydrogen feedstock. The company currently is producing bioacrylic at pilot scale in advance of opening a demonstration plant in 2011 and a full-scale commercial plant in 2013. The company also is developing strategic partnerships and joint ventures for commercialization.

OPXBIO has raised $22.4 million with venture investors Mohr Davidow Ventures, Braemar Energy Ventures, Altira Group, and X/Seed Capital.

For more information, visit http://www.opxbio.com.


Media Contact:

Brandy Radey
Cohn Marketing
303.839.1415 ext. 55
Email Contact



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES